Cited 0 times in
Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.contributor.author | 정준원 | - |
dc.date.accessioned | 2021-12-28T16:56:48Z | - |
dc.date.available | 2021-12-28T16:56:48Z | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186865 | - |
dc.description.abstract | Background/aims: Compared with Western countries, chronic lymphocytic leukemia (CLL) rarely occurs in Asia and has different clinical characteristics. Thus, we aimed to evaluate the clinical characteristics, treatment outcomes, and prognostic significance of Korean patients with CLL. Methods: We retrospectively analyzed 90 patients with CLL who had received chemotherapy at 6 centers in Korea between 2000 and 2012. Results: Compared with Western patients with CLL, Korean patients with CLL express lambda (42.0%) and atypical markers such as CD22 and FMC7 (76.7% and 40.0%, respectively) more frequently. First-line chemotherapy regimens included chlorambucil (n = 43), fludarabine and cyclophosphamide (FC) (n = 20), fludarabine (n = 13), rituximab-FC (n = 4). The remaining patients were treated with other various regimens (n = 10). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 79.3% and 28.1%, respectively. Multivariate analyses showed that hyperleukocytosis (≥ 100 × 103/μL), extranodal involvement, and the Binet C stage were significant negative prognostic factors for OS (hazard ratio [HR] 4.75, p = 0.039; HR 21.6, p = 0.002; and HR 4.35, p = 0.034, respectively). Cytogenetic abnormalities including complex karyotypes (≥ 3), del(11q), and del(17) had a significantly adverse impact on both OS and PFS (p < 0.001 and p = 0.010, respectively). Conclusion: Initial hyperleukocytosis, extranodal involvement, complex karyotype, del(17) and del(11q) need to be considered in the risk stratification system for CLL. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Association of Internal Medicine | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Asia | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis | - |
dc.subject.MESH | Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Rituximab / therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vidarabine / adverse effects | - |
dc.title | Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yunsuk Choi | - |
dc.contributor.googleauthor | Jung-Hee Lee | - |
dc.contributor.googleauthor | Chul Won Jung | - |
dc.contributor.googleauthor | Jae-Cheol Jo | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Inho Kim | - |
dc.contributor.googleauthor | Silvia Park | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Sang-Hyuk Park | - |
dc.contributor.googleauthor | Sung-Yong Kim | - |
dc.contributor.googleauthor | Hong-Ghi Lee | - |
dc.identifier.doi | 10.3904/kjim.2019.210 | - |
dc.contributor.localId | A01017 | - |
dc.contributor.localId | A03729 | - |
dc.relation.journalcode | J02883 | - |
dc.identifier.eissn | 2005-6648 | - |
dc.identifier.pmid | 32279477 | - |
dc.subject.keyword | Korean | - |
dc.subject.keyword | Leukemia, lymphocytic, chronic, B-cell | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Treatment outcome | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.contributor.affiliatedAuthor | 정준원 | - |
dc.citation.volume | 36 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 194 | - |
dc.citation.endPage | 204 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, Vol.36(1) : 194-204, 2021-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.